Cabazitaxel Improves rPFS in Patients with mCRPC

Daniel P. Petrylak, MD, discusses the efficacy results from the CARD trial, which evaluated the radiographic progression-free survival of cabazitaxel combined with either abiraterone acetate or enzalutamide in patients with metastatic castration-resistant prostate cancer.<br /> &nbsp;

Daniel P. Petrylak, MD, professor of medicine and urology and co-leader, Cancer Signaling Networks, Yale Cancer Center, discusses the efficacy results from the CARD trial, which evaluated the radiographic progression-free survival (rPFS) of cabazitaxel (Jevtana) combined with either abiraterone acetate (Zytiga) or enzalutamide (Xtandi) in patients with metastatic castration-resistant prostate cancer (mCRPC).

The results showed that the use of cabazitaxel achieved better rPFS than either second-generation antiandrogen. This suggests that patients still have resistance to second-generation hormonal agents but, currently, there is no algorithm for understanding which agent should be administered and when.